Jul 2026
A novel peptide-MHC-based T cell engager synergizes with tumor-targeted IL-12 for immunotherapy of solid tumors.
Conventional CD3-targeting bispecific T cell engagers (BiTEs) have shown limited efficacy in solid tumors, largely due to the highly immunosuppressive tumor microenvironment (TME) and systemic T cell activation-associated toxicity. To address this challenge, we developed a peptide-MHC class I-based T cell engager platf...
Shihui Wang, Qing Xu, Xueqian Peng et al.
· International Immunopharmaco... · 0 citations